Summary

One of the more difficult issues that clinicians face when helping patients make adjuvant therapy decisions is what to do when discordance exists between two important predictors of relapse risk: tumor stage and tumor biology [Albain KS. SABCS 2012 (abstr CS1–1)]. Patients with higher-stage tumors (ie, large tumors, multiple positive lymph nodes) of favorable biology (eg, luminal A tumors) and those with the opposite situation (ie, small tumors with aggressive biology) can render adjuvant therapy choices difficult.